MoonLake Immunotherapeutics (MLTX) Depreciation and Depletion (2021 - 2024)
MoonLake Immunotherapeutics' Depreciation and Depletion history spans 4 years, with the latest figure at $32515.0 for Q3 2024.
- Quarterly Depreciation and Depletion rose 888.3% to $32515.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $86729.0 through Sep 2024, up 559.14% year-over-year, with the annual reading at $13158.0 for FY2023, 6.47% up from the prior year.
- Depreciation and Depletion came in at $32515.0 for Q3 2024, up from $28112.0 in the prior quarter.
- In the past five years, Depreciation and Depletion ranged from a high of $32515.0 in Q3 2024 to a low of $2271.0 in Q3 2021.
- The 4-year median for Depreciation and Depletion is $3290.0 (2023), against an average of $8938.3.
- Year-over-year, Depreciation and Depletion crashed 33.84% in 2022 and then surged 888.3% in 2024.
- MoonLake Immunotherapeutics' Depreciation and Depletion stood at $4971.0 in 2021, then crashed by 33.84% to $3289.0 in 2022, then changed by 0.0% to $3289.0 in 2023, then skyrocketed by 888.6% to $32515.0 in 2024.
- Per Business Quant, the three most recent readings for MLTX's Depreciation and Depletion are $32515.0 (Q3 2024), $28112.0 (Q2 2024), and $22813.0 (Q1 2024).